RenovaroRENB
RENB
About: Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
Employees: 25
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
183% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 6
100% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 7
33% more call options, than puts
Call options by funds: $12K | Put options by funds: $9K
28% more funds holding
Funds holding: 39 [Q2] → 50 (+11) [Q3]
0.09% more ownership
Funds ownership: 9.92% [Q2] → 10.01% (+0.09%) [Q3]
72% less capital invested
Capital invested by funds: $25.6M [Q2] → $7.13M (-$18.4M) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for RENB.
Financial journalist opinion
Neutral
GlobeNewsWire
16 hours ago
Renovaro Regains Compliance with NASDAQ Listing Requirement
LOS ANGELES, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced that it has received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule, 5550(a)(2). The Company's security will continue to be listed and traded on The Nasdaq Stock Market and this matter is now closed.
Neutral
GlobeNewsWire
22 hours ago
Renovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection
Renovaro will Establish the GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's certified AI Healthcare Cloud solutions LOS ANGELES, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced its subsidiary Renovaro Cube (the “Cube”), a leader in specific AI-driven healthcare solutions, has entered into a strategic collaboration with Nebul (www.nebul.com) a leading AI cloud infrastructure company, to advance the early detection of cancer and other diseases. Nebul is a European NVIDIA NPN DGX Preferred Cloud Service Provider providing world-class supercomputing and GPU-accelerated business computing services, and a preferred cloud service provider in the NVIDIA Partner Network.
Neutral
GlobeNewsWire
1 month ago
Renovaro Issues Shareholder Letter and Provides Corporate Update
LOS ANGELES, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today issued a letter to shareholders from Chief Executive Officer David Weinstein. Dear Shareholders, It is my honor to address you as the newly appointed CEO of Renovaro Inc. After careful consideration, I left a 40-year career on Wall Street to join Renovaro because I believe the Company has tremendous potential in its verticals, such as the dendritic cancer cell vaccine (DCCV) and AI powered multi-cancer early detection screening and therapeutics.
Neutral
GlobeNewsWire
2 months ago
RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing
AMSTERDAM, Oct. 17, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) – RenovaroCube, a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies, is excited to announce the presentation of its latest research at the Molecular Analysis for Precision Oncology Congress – on October 16, 2024.
Neutral
GlobeNewsWire
2 months ago
Renovaro Announces Strategic Restructuring and Leadership Transition
LOS ANGELES, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced a strategic restructuring and leadership transition of senior management and the Board of Directors to realign resources focused on the Company's AI Platform, RenovaroCube for multi-cancer early detection and patient monitoring. The Board, with the support of a supermajority of shareholders, appointed David Weinstein as director and new CEO and four new directors – Maurice van Tilburg, Chairman, Douglas Calder, James A. McNulty CPA, and Mark A. Collins PhD.
Neutral
GlobeNewsWire
3 months ago
RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress
AMSTERDAM, Sept. 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) RenovaroCube (Cube, the Company), a leading AI-driven innovator using multi-omics technology for cancer profiling, is pleased to announce two scientific presentations at a leading cancer conference – the European Society for Medical Oncology (ESMO) Congress – on September 15, 2024.
Neutral
GlobeNewsWire
3 months ago
RenovaroCube Announces Strategic Offering of Up to 20% Ownership
AMSTERDAM, Sept. 11, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) The Board of Renovaro, Inc (RENB) intends to seek strategic investors to acquire up to 20% of RenovaroCube (Cube), currently a wholly owned subsidiary.
Neutral
GlobeNewsWire
6 months ago
Renovaro, Inc. Announces $10 million in Equity Committed
LOS ANGELES, June 14, 2024 (GLOBE NEWSWIRE) -- Renovaro, Inc. (NASDAQ: RENB) (the “Company”) announces that it has $10 million in additional equity committed at a price per share of $1.4726 and 10 percent warrant coverage. “We appreciate confidence in the Company demonstrated by the investors,” said the Hon.
Neutral
GlobeNewsWire
6 months ago
Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy
LOS ANGELES and AMSTERDAM, May 24, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB) and the Amsterdam UMC Cancer Center today announced an intended partnership and therefore signed an MoU to establish a joint company based in the Netherlands aimed at pioneering the next generation of personalized cancer immunotherapy. Both Renovaro and Amsterdam UMC emphasize the need to carry out the appropriate corporate and scientific due diligence before taking these next steps.
Positive
Benzinga
7 months ago
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Renovaro (NASDAQ:RENB)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Charts implemented using Lightweight Charts™